Alto Neuroscience (ANRO) Exchange Rate Effect (2023 - 2026)
Alto Neuroscience (ANRO) posted Exchange Rate Effect of -$16000.0 for Q1 2026, down 1500.0% sequentially from -$1000.0 in Q4 2025, and up 27.27% YoY from -$12571.4 in Q1 2025.
Powered by 
Analysis
Alto Neuroscience (ANRO) Exchange Rate Effect (2023 - 2026) Analysis & Trends
Alto Neuroscience has reported Exchange Rate Effect for 4 years, with the latest figure at -$16000.0 in Q1 2026.
- Quarterly Exchange Rate Effect rose 27.27% year-over-year to -$16000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$24000.0 (up 14.29% YoY) and the FY2025 annual result came in at -$30000.0, down 172.73% from the prior year.
- Exchange Rate Effect retreated to -$16000.0 in Q1 2026 per ANRO's latest filing, from -$1000.0 in the prior quarter.
- Over five years, Exchange Rate Effect peaked at $18000.0 in Q3 2023 and troughed at -$22000.0 in Q1 2025.
- A 4-year average of -$5000.0 and a median of -$5000.0 in 2024 frame the typical range for Exchange Rate Effect.
- The sharpest annual moves came in 2024 and 2025: Exchange Rate Effect jumped 73.68% in 2024, then sank 340.0% in 2025.
- Over 4 years, Exchange Rate Effect stood at $4000.0 in 2023, then jumped by 50.0% to $6000.0 in 2024, then slumped by 116.67% to -$1000.0 in 2025, then slumped by 1500.0% to -$16000.0 in 2026.
- According to Business Quant data, Exchange Rate Effect over the past three periods registered -$16000.0, -$1000.0, and -$4000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Exchange Rate Effect (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -3.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -300,000.00 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -2.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 19.84 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -2.45 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -287,000.00 |
| 10 | Alto Neuroscience | 1.52 Bn | 1.52 Bn | - | 4,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 4,000.00 |
| Mar 31, 2026 | -16,000.00 |
| Dec 31, 2025 | -1,000.00 |
| Sep 30, 2025 | -4,000.00 |
| Jun 30, 2025 | -3,000.00 |
| Mar 31, 2025 | -22,000.00 |
| Dec 31, 2024 | 6,000.00 |
| Sep 30, 2024 | -7,000.00 |
| Jun 30, 2024 | -5,000.00 |
| Mar 31, 2024 | -5,000.00 |
| Dec 31, 2023 | 4,000.00 |
| Sep 30, 2023 | 18,000.00 |
| Jun 30, 2023 | -11,000.00 |
| Mar 31, 2023 | -19,000.00 |